A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

NCT00354146 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Nonlymphocytic, Acute

Interventions

DRUG: tipifarnib (R115777)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.